HIV molecular immunology database
Found 1 matching record:
| HXB2 Location | Gag(263-272) | Gag Epitope Map
View variants at this location |
|||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epitope |
KRWIILGLNK
|
Epitope Alignment | |||||||||||||||||||||||||||||||||||||||||||
| Variants |
|
||||||||||||||||||||||||||||||||||||||||||||
| Epitope Name | KK10 | ||||||||||||||||||||||||||||||||||||||||||||
| Species (MHC/HLA) | human(B*27:05) | ||||||||||||||||||||||||||||||||||||||||||||
Showing all: 14 variant(s).
| Variant ID. | 1596 |
|---|---|
| Epitope Seq. | KRWIILGLNK |
| Variant Seq. | KkWIILGLNK |
| Mutations | R/K |
| Epitope Location | R2K |
| HXB2 Location | R264K |
| Mutation Type | DHB: diminished HLA binding or increased off-rate RCR: replicative capacity reduced |
| Method | HLA binding, Relative replication capacity assay |
| Note | This R264K mutation, which is not seen in vivo, abrogates replicative capacity of the virus. Decreased HLA-B27 binding results. Increased infectivity is seen when treated with Cyclosporin A. |
| Variant ID. | 1597 |
|---|---|
| Epitope Seq. | KRWIILGLNK |
| Variant Seq. | KRWIImGLNK |
| Mutations | L/M |
| Epitope Location | L6M |
| HXB2 Location | L268M |
| Mutation Type | RCOK: replicative capacity is not abrogated |
| Method | HLA binding, Relative replication capacity assay |
| Note | This natural L268M mutation does not affect replicative capacity of the virus or binding to HLA-B27. A decrease in the influence of Cyclosporin A is seen on infectivity. |
| Variant ID. | 1598 |
|---|---|
| Epitope Seq. | KRWIILGLNK |
| Variant Seq. | KkWIImGLNK |
| Mutations | R/K L/M |
| Epitope Location | R2K L6M |
| HXB2 Location | R264K L268M |
| Mutation Type | DHB: diminished HLA binding or increased off-rate RCR: replicative capacity reduced |
| Method | HLA binding, Relative replication capacity assay |
| Note | This natural R264K, L268M mutation abrogates replicative capacity of the virus. Decreased HLA-B27 binding results. Increased infectivity is seen when treated with Cyclosporin A. |
| Variant ID. | 1599 |
|---|---|
| Epitope Seq. | KRWIILGLNK |
| Variant Seq. | KtWIILGLNK |
| Mutations | R/T |
| Epitope Location | R2T |
| HXB2 Location | R264T |
| Mutation Type | DHB: diminished HLA binding or increased off-rate RCOK: replicative capacity is not abrogated |
| Method | HLA binding, Relative replication capacity assay |
| Note | This natural R264T mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A. |
| Variant ID. | 1600 |
|---|---|
| Epitope Seq. | KRWIILGLNK |
| Variant Seq. | KtWIImGLNK |
| Mutations | R/T L/M |
| Epitope Location | R2T L6M |
| HXB2 Location | R264T L268M |
| Mutation Type | DHB: diminished HLA binding or increased off-rate RCOK: replicative capacity is not abrogated |
| Method | HLA binding, Relative replication capacity assay |
| Note | This natural R264T, L268M double mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A. |
| Variant ID. | 1601 |
|---|---|
| Epitope Seq. | KRWIILGLNK |
| Variant Seq. | KqWIILGLNK |
| Mutations | R/Q |
| Epitope Location | R2Q |
| HXB2 Location | R264Q |
| Mutation Type | DHB: diminished HLA binding or increased off-rate RCOK: replicative capacity is not abrogated |
| Method | HLA binding, Relative replication capacity assay |
| Note | This R264Q variant is not seen in vivo, and does not affect replicative capacity. Severely decreased HLA-B27 binding does, however, result with decrease in infectivity when treated with Cyclosporin A. |
| Variant ID. | 1602 |
|---|---|
| Epitope Seq. | KRWIILGLNK |
| Variant Seq. | KqWIImGLNK |
| Mutations | R/Q L/M |
| Epitope Location | R2Q L6M |
| HXB2 Location | R264Q L268M |
| Mutation Type | DHB: diminished HLA binding or increased off-rate RCOK: replicative capacity is not abrogated |
| Method | HLA binding, Relative replication capacity assay |
| Note | This natural R264Q, L268M double mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A. |
| Variant ID. | 1603 |
|---|---|
| Epitope Seq. | KRWIILGLNK |
| Variant Seq. | KgWIILGLNK |
| Mutations | R/G |
| Epitope Location | R2G |
| HXB2 Location | R264G |
| Mutation Type | RCOK: replicative capacity is not abrogated |
| Method | HLA binding, Relative replication capacity assay |
| Note | This natural R264G mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A. |
| Variant ID. | 2311 |
|---|---|
| Epitope Seq. | {S...}KRWIILGLNK |
| Variant Seq. | {a...}KkWIImGLNK |
| Mutations | R/K L/M S/A |
| Epitope Location | R2K L6M S-90A |
| HXB2 Location | R264K L268M S173A |
| Mutation Type | DHB: diminished HLA binding or increased off-rate RCOK: replicative capacity is not abrogated |
| Method | HLA binding, Relative replication capacity assay |
| Note | This triple S173A, R264K , L268M natural mutation does not affect replicative capacity of the virus, and brings its activity back to that of wild type. Decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A. |
| Variant ID. | 2312 |
|---|---|
| Epitope Seq. | {S...}KRWIILGLNK |
| Variant Seq. | {t...}KtWIImGLNK |
| Mutations | R/T L/M S/T |
| Epitope Location | R2T L6M S-90T |
| HXB2 Location | R264T L268M S173T |
| Mutation Type | DHB: diminished HLA binding or increased off-rate RCOK: replicative capacity is not abrogated |
| Method | HLA binding, Relative replication capacity assay |
| Note | This natural S173T, R264T, L268M triple mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. |
| Variant ID. | 2313 |
|---|---|
| Epitope Seq. | {E**}KRWIILGLNK |
| Variant Seq. | {d**}KRWIILGLNK |
| Mutations | E/D |
| Epitope Location | E-3D |
| HXB2 Location | E260D |
| Mutation Type | RCOK: replicative capacity is not abrogated |
| Method | HLA binding, Relative replication capacity assay |
| Note | This natural, upstream E260D mutation increases replicative capacity and retains binding to HLA-B27. Decreased infectivity is seen when treated with Cyclosporin A. |
| Variant ID. | 2314 |
|---|---|
| Epitope Seq. | {E**}KRWIILGLNK |
| Variant Seq. | {d**}KgWIILGLNK |
| Mutations | R/G E/D |
| Epitope Location | R2G E-3D |
| HXB2 Location | R264G E260D |
| Mutation Type | DHB: diminished HLA binding or increased off-rate RCR: replicative capacity reduced |
| Method | HLA binding, Relative replication capacity assay |
| Note | This natural E260D, R264G double mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A. |
| Variant ID. | 2315 |
|---|---|
| Epitope Seq. | {E**}KRWIILGLNK |
| Variant Seq. | {d**}KgWIImGLNK |
| Mutations | R/G E/D L/M |
| Epitope Location | R2G E-3D L6M |
| HXB2 Location | R264G E260D L268M |
| Mutation Type | RCR: replicative capacity reduced |
| Method | HLA binding, Relative replication capacity assay |
| Note | This E260D, R264G, L268M triple mutation greatly affects replicative capacity. It is not seen in vivo. |
| Variant ID. | 2316 |
|---|---|
| Epitope Seq. | {E**}KRWIILGLNK |
| Variant Seq. | {d**}KkWIILGLNK |
| Mutations | R/K E/D |
| Epitope Location | R2K E-3D |
| HXB2 Location | R264K E260D |
| Mutation Type | DHB: diminished HLA binding or increased off-rate RCR: replicative capacity reduced |
| Method | HLA binding, Relative replication capacity assay |
| Note | This E260D, R264K double mutation is not found in vivo and greatly affects replicative capacity. Decreased HLA-B27 binding results. |
Schneidewind2008 Arne Schneidewind, Mark A Brockman, John Sidney, Yaoyu E Wang, Huabiao Chen, Todd J Suscovich, Bin Li, Rahma I Adam, Rachel L Allgaier, Bianca R Mothé, Thomas Kuntzen, Cesar Oniangue-Ndza, Alicja Trocha, Xu G Yu, Christian Brander, Alessandro Sette, Bruce D Walker, and Todd M Allen. Structural and Functional Constraints Limit Options for Cytotoxic T-Lymphocyte Escape in the Immunodominant HLA-B27-Restricted Epitope in Human Immunodeficiency Virus Type 1 Capsid. J. Virol., 82(11):5594-5605, Jun 2008. PubMed ID: 18385228. Show all entries for this paper.